Acutelines: a Large Biobank Aiming to Improve Early Recognition of Acute Diseases, Contribute to the Development of Personalized Medicine and Optimize Short- and Long-term Outcome
Led by University Medical Center Groningen · Updated on 2024-06-13
35000
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
Brief Title
Who Can Participate
AI-Screening
Your Study Journey
Trial Site Locations
Research Team
How is the study designed?
Similar Trials
Frequently Asked Questions
Research Publications
AI-Summary
What this Trial Is About
Researchers are conducting a study called Acutelines, a large data and biobank project at the University Medical Center Groningen in the Netherlands. It focuses on patients with a wide range of acute medical conditions who present to the Emergency Department. The goal is to improve how acute diseases are recognized and treated, understand their outcomes, and support personalized medicine by collecting detailed clinical data, imaging, and biomaterials over time.
Participants have their medical information, including demographics, health status, medical history, vital signs, diagnostic tests, and treatments, systematically collected. Biomaterials such as blood, urine, feces, and hair are gathered from patients who meet certain severity criteria. Data collection occurs during hospital admission, including continuous monitoring, and continues with follow-ups at 3 months, 1 year, 2 years, and 5 years after the initial emergency visit.
Throughout the study, various assessments are performed, such as quality of life, physical functioning, mental health, symptoms, and hospital length of stay. Researchers collect data on mortality and other health outcomes for up to 50 years. The study uses digital tools to automate data capture and integrates information from multiple healthcare sources. Participants will be monitored closely during hospitalization and at scheduled intervals afterward to help improve understanding and treatment of acute diseases.
CONDITIONS
Brief Title
Acutelines: a Large Data-/Biobank of Acute and Emergency Medicine
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Adults aged 18 years or older
Triaged as one of the highest two categories (red or orange) by the Manchester triage system
Or triaged as the third highest category (yellow) and arrived by Helicopter Emergency Medical Service (HEMS)
Experiencing shock
Suspected sepsis based on clinical criteria
Acute kidney injury
Anaphylactic reaction
Syncope
Intoxication
Thrombosis
Pulmonary embolism
Bleeding while using anti-coagulant drugs
Gastro-intestinal bleeding
Electrolyte disturbance
You will not qualify if you...
Referred for organ transplantation as recipient
Transferred from another hospital
Accidental contact patient material such as internal work-related accidents
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Diagnostic Evaluation
Duration - During hospital admission
Participants presenting to the Emergency Department have clinical data, imaging data, and biomaterials collected to evaluate their acute condition.
Initial ED visit and assessments during hospitalization
Monitoring
Duration - Up to 72 hours
Participants are monitored through collection of clinical data, vital parameters, and biomaterials during the first 72 hours of hospitalization.
Continuous monitoring during hospital stay
Long-term Monitoring
Duration - Up to 5 years
Participants are followed up to collect outcome data related to health, functioning, and quality of life after their ED visit.
Follow-up visits or assessments at 3 months, 1 year, 2 years, and 5 years after ED visit
Validation of plasma microRNAs as biomarkers in sepsis associated acute kidney injury upon first clinical presentation reveals limited diagnostic and prognostic performance.
Tamar J van der Aart, Matthijs Luxen, Jacqueline Koeze...